Page 56 - KIDNEY CANCER

*
Progression-free Survival With Lenvatinib Plus

Pembrolizumab in Key Subgroups

LEN + PEMBRO SUN
Subgroup Events / no. of patients HR (95% CI)

Overall 160/355 205/357 0.39 (0.32–0.49)
Age
< 65 years 88/194 134/225 0.37 (0.28–0.49)
≥ 65 years 72/161 71/132 0.43 (0.31–0.61)
Sex
Male 120/255 158/275 0.38 (0.30–0.49)
Female 40/100 47/82 0.42 (0.27–0.66)
Geographic region
Western Europe and NA 86/198 108/199 0.42 (0.32–0.57)
Rest of the World 74/157 97/158 0.36 (0.26–0.49)
PD-L1 expression
≥ 1 51/107 78/119 0.40 (0.27–0.58)
< 1 48/112 58/103 0.39 (0.26–0.59)
IMDC risk group
Favorable 43/110 67/124 0.41 (0.28–0.62)
Intermediate 97/210 110/192 0.39 (0.29–0.52)
Poor 18/33 26/37 0.28 (0.13–0.60)
Prior nephrectomy
Yes 107/262 163/275 0.37 (0.28–0.47)
No 53/93 42/82 0.44 (0.28–0.68)
Sarcomatoid features
Yes 19/28 16/21 0.39 (0.18–0.84)
No 141/327 189/336 0.38 (0.31–0.48)

*By Independent Review Committee per RECIST v1.1. 0.1 1 2
NA, North America. Favors LEN + PEMBRO Favors SUN